Intrinsiqq
Replimune Group Inc. logo

Replimune Group Inc.

REPL

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$1.81B
EPS-$2.79
P/E-6.83
P/FCF-7.36
EV/EBITDA-6.03
FCF Yield–
Div. Yield–
Net Debt/FCF0.7x
Replimune Group Inc. intrinsic value
52-Week Range
$4.07$23.28

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$271M

▼ -26.9% YoY

Op. Margin

–

ROIC

-76.50%

▼ -21.8pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$246M

▼ -43.0% YoY

Op. Cash Flow (TTM)

-$246M

▼ -45.8% YoY

Net Debt

-$181M

Net Cash Position

Cash & Equiv.

$308M

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with REPL

CompareIntrinsic value
ARTVArtiva Biotherapeutics Inc.
$3.78-1.31%10
SRZNSurrozen, Inc.
$28.46-7.21%10
CHRSCoherus Biosciences Inc.
$0.37-4.44%10
DNAGinkgo Bioworks Holdings Inc.
$7.46-9.02%15
IMAImageneBio, Inc.
$3.92-1.51%10
EDITEditas Medicine Inc.
$1.64-4.09%40
CMPXCompass Therapeutics Inc.
$0.69+1.40%10
IBRXImmunityBio, Inc.
$6.02-8.37%30

Held by ETFs

REPL is in 26 US ETFs. The largest of them, with REPL's weight in each:

Replimune Group (REPL) in two numbers

Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-6.83
Negative: a loss over the last twelve months. Price to free cash flow -7.36.
Financials

Questions about Replimune Group

Does Replimune Group (REPL) pay a dividend?

No. Replimune Group (REPL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 23 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in REPL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing REPL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.